AVYXA Pharma, LLC has secured FDA approval for NAVITRUX (fosaprepitant dimeglumine) Intravenous injection, positioning the pharmaceutical company to expand its hematology and myeloma portfolio while capitalizing on the prevention of postoperative nausea and vomiting. This approval is expected to strengthen AVYXA's commercial footprint and address critical anemia management needs in the oncology and hematologic markets.